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INTRODUCTION
The metabolic syndrome is an important cluster of coronary heart
disease risk factors linked to insulin resistance. It has been esti-
mated that approximately 24% of American adults have the syn-
drome, and there is reason to believe that there is a worldwide
increase in the incidence and prevalence of this atherogenic phe-
notype (Ford et al., 2002). People with the metabolic syndrome
are at increased risk for developing diabetes mellitus (Haffner et
al., 1992) and cardiovascular disease (CVD) (Isomaa et al.,
2001), and face an increased risk of mortality from CVD and all
causes (Trevisan et al., 1998). A working definition of this syn-
drome was formulated by the recently released Third Report of
the National Cholesterol Education Program Expert Panel on
Detection, Evaluation and Treatment of High Blood Cholesterol
in Adults (National Institutes of Health, 2001).
The hallmarks of the metabolic syndrome include increased
body weight and waist circumference (central and abdominal
obesity), elevated plasma glucose, an atherogenic lipoprotein pro-
file (high blood TG and small, dense LDL-C levels and low blood
levels of HDL-C), and raised blood pressure. 
Therapeutic lifestyle changes have been shown to reverse the
pathophysiology of the metabolic syndrome, improve biomarkers
of the risk factors and reduce the prevalence of the associated car-
diovascular risk (Esposito et al., 2004). Mediterranean-type
dietary changes combined with mild exercise and weight loss are
key therapeutic objectives in the prevention and treatment of the
metabolic syndrome. Modest weight reduction has been associat-
ed with clinically significant improvements in diabetes-associat-
ed mortality (Heilbronn et al., 1999), hypertension (Tuck et al.,
1981), lipid abnormalities (Dattilo and Kris-Etherton, 1992), and
glycaemic control.
It is well documented that dietary changes comprising
increased servings of fruits, vegetables and high-fibre whole
grains, legumes, walnuts, olive oil and fish, and a moderate alco-
hol intake, are inversely correlated with coronary heart disease,
whereas foods of animal origin are directly correlated (Menotti et
al., 1999). Populations consuming a Mediterranean diet (MD)
had the lowest mortality among the populations of seven coun-
tries included in the study of Menotti et al. (1999).
The Lyon Diet Heart Study convincingly demonstrated that the
Mediterranean α-linolenic acid-rich diet achieved greater reduc-
*Corresponding author: e-mail: dpvv@sun.ac.za
Acknowledgements: The authors wish to thank Winetech (Wine Industry Network of Expertise and Technology), South Africa, for contributing to this research, Dr Martin
Kidd, for the statistical analysis, and Ms Ingrid September, for the financial administration. The South African version of a Mediterranean-type diet was designed by Dr
P Wolmarans, Nutritional Intervention Research Unit, Medical Research Council, South Africa.
The Short-term Influence of a Mediterranean-type Diet and Mild Exercise
with and without Red Wine on Patients with the Metabolic Syndrome
D.P. van Velden1*, S. van der Merwe1, E. Fourie1, M. Kidd1, D.M. Blackhurst2, M.J. Kotze3 and E.P.G. Mansvelt1
(1) Faculty of Health Sciences, Stellenbosch University, PO Box 19063, Tygerberg 7505, South Africa
(2) Lipidology Division of Internal Medicine, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory 7925,
South Africa
(3) Genecare Molecular Genetics (Pty) Ltd, Christiaan Barnard Memorial Hospital, Cape Town, South Africa
Submitted for publication: January 2007
Accepted for publication: May 2007
Key words: Mediterranean diet, red wine, metabolic syndrome.
The metabolic syndrome is a target for the dietary prevention of cardiovascular disease. The effect of adding red
wine to the diet has not been fully investigated. This study examined whether a Mediterranean-type diet
complemented with red wine and mild exercise had an impact on patients with the metabolic syndrome in the short
term. Twelve patients with the metabolic syndrome consumed a Mediterranean-type diet for four weeks without
and with red wine respectively and performed mild exercise. We implemented the diagnostic criteria for the
metabolic syndrome as formulated by the Adult Treatment Panel III (ATP III) in 2001. The patients were also
screened for multiple genetic markers implicated in cardiovascular disease. Weight, body mass index, abdominal
circumference and blood pressure were measured, as well as various biochemical, haematological and
inflammatory markers. There was a significant decrease in the body weight (p = 0.04) and an increase in ORAC
value (p = 0.035) after the dietary intervention. A significant decrease in systolic blood pressure (p = 0.045) was
observed. Red wine had no additional benefits. Although diet reduced weight and blood pressure, the lipoprotein
and pro-coagulant profiles of patients with the metabolic syndrome were not affected in this study. These findings
may be explained partly by the diverse genetic profile identified among the study participants, as 50% had
mutations involved in lipid metabolism that may influence the response to dietary intervention and alcohol
consumption.
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tions in the risk of all-cause mortality and coronary heart disease
mortality in a secondary prevention trial than any of the choles-
terol-lowering studies to date (De Logeril et al., 1999).
Epidemiologic studies have consistently shown an inverse cor-
relation between HDL-C levels and the risk of cardiovascular dis-
ease (Brewer, 2004; Alsheikh-Ali et al., 2005). In the past decade,
high-density lipoproteins (HDL) have emerged as a new potential
therapeutic target for the treatment of CVD. The key role of
HDL-C is that of a carrier of excess cellular cholesterol in the
reverse cholesterol transport pathway, a process by which free
cholesterol is removed from peripheral tissue, including blood
vessels, for transfer back to the liver and, ultimately, excretion in
the bile. HDL-C and Apo-A1 have also been shown to protect
LDL particles against oxidative modification and reverse the
inhibitory effects of oxidised LDL on endothelial function
(Mackness et al., 1993; Naval et al., 2002). HDL-C may also
slow the progression of lesions by selectively decreasing the pro-
duction of endothelial cell-adhesion molecules that facilitate the
uptake of cells into the vessel wall (Barter et al., 2002). Other
studies have also demonstrated direct antioxidant, anti-inflamma-
tory, anti-thrombotic and pro-fibrinolytic effects of HDL (Shah et
al., 2001; Kuvin and Karas, 2003).
Aerobic exercise and weight loss increase HDL-C (O’Conner
et al., 1995). Aerobic exercise and weight loss have also been
demonstrated to improve insulin sensitivity and lower blood pres-
sure, thus correcting many abnormalities associated with the
insulin resistance syndrome (Hunter and Garvey, 1998; Despres,
2005). Recent studies demonstrate that dietary modification and
enhanced physical activity (Schoeller et al., 1997) may delay or
prevent the transition from impaired glucose tolerance to type 2
diabetes mellitus (Goodpasture et al., 2003). It is well document-
ed that low cardio-respiratory fitness is an important risk marker
for the metabolic syndrome, and an increase in physical activi-
ty/exercise is essential to reverse the abnormal metabolic changes
in this atherogenic phenotype. It has also been demonstrated that,
provided the stimulus is adequate, regular physical activity and
endurance training can promote body fat loss and a mobilisation
of abdominal and visceral adipose tissue, increase muscle mass
and insulin sensitivity, and reverse the atherogenic lipoprotein
profile, as well as other features of the metabolic syndrome,
including inflammation (Despres et al., 2001).
Moderate alcohol consumption may have beneficial effects by
decreasing insulin resistance, increasing HDL-C (Gaziano et al.,
1993) and reducing platelet aggregation (Ridker et al., 1997).
Ethanol in the diet reduces the risk of coronary heart disease and
diabetes. In healthy adults, ethanol causes hypoglycaemia through
the inhibition of gluconeogenesis and glycogen catabolism. Ethanol
also augments insulin release, similar to the sulfonylurea drugs,
leading to a transient hyperinsulinaemia, which can also serve to
accelerate clearance of glucose from the blood (Bisson et al., 1995).
It has been demonstrated that alcohol consumption is associated
with lower levels of inflammation, as measured by C-reactive pro-
tein, WBC, fibrinogen, VIIIc and albumin (Mukamal et al., 2004).
Objectives
In this study, we aimed to evaluate the added effect of moderate
red wine consumption and mild exercise with the Mediterranean-
type diet on CVD risk factors in subjects with the metabolic syn-
drome during a two-month intervention period. The end points
were observed changes in risk factors (clinical variables and bio-
chemical markers) after one month of the diet and after one
month of the diet plus wine intervention.
MATERIALS AND METHODS
Our study included 12 non-smoking subjects, on no medication
influencing platelet aggregation and lipoprotein profile, between
the ages of 32 and 60 years and with the diagnostic criteria of the
metabolic syndrome. As detailed in the ATP III report (executive
summary), we used the following criteria to diagnose the meta-
bolic syndrome: abdominal obesity: waist circumference >102
cm in men and >88 cm in women; hypertriglyceridaemia: ≥1.69
mmol/L; low HDL-C: <1.0 mmol/L in men and <1.3 mmol/L in
women; high blood pressure: ≥130/85 mm Hg, and high fasting
glucose: ≥6.1 mmol/L (National Institutes of Health, 2001).
Participants having three or more of these criteria were defined as
having the metabolic syndrome.
The participants consumed a Mediterranean-type diet for four
weeks without and with red wine respectively. During the experi-
mental periods, the subjects increased their intake of vegetables,
cereals, fruit, mono-unsaturated fatty acids and fish at the expense
of red meat and dairy products (Figure 1). The dietary guidelines for
the Mediterranean-type diet included the following: wholegrain/
brown bread and whole-wheat cereal products should preferably be
consumed; fish should be included in the diet at least twice per week
and at least one portion should be fatty fish; chicken without skin
can be included in the diet; not more than two portions of red meat
(2 x 150 g for men and 2 x 120 g for women, cooked weight) should
be consumed per week; no more than 60 g hard cheese (e.g.
Cheddar) should be consumed per week; canola or olive oil should
be used for food preparation, within the fat allowance; canola or
olive oil margarine should be used as bread spread, and red wine
consumption should be 250 mL for men and 180 mL for women per
day. We supplied the candidates with a variety of good quality South
African red wines with a mild antioxidant potential.
Dietary information was collected by means of three-day
weighed and estimated dietary records (including one weekend
day), covering the last three days of the baseline period, and dur-
ing the third week of the different experimental periods. Subjects
received verbal and written instructions before the start of the
study on record keeping and estimating and weighing food por-
tions. Dietary records were checked after three days by a regis-
tered dietician for completeness and for compliance with the
dietary prescriptions. The National Research Institute for
Nutritional Diseases (NRIND) Food Composition Tables (Gouws
and Langenhoven, 1986) were used for encoding the type of food
eaten and, if the food was not weighed, the NRIND Food
Quantities Manual (Langenhoven et al., 1986) was used to con-
vert the amount of food reported in household measures into
grams of food eaten. Dietary data were analysed for energy,
macronutrients, cholesterol and fatty acid intake.
The subjects were motivated to include 20 to 30 min of mild
exercise (brisk walking) in their daily routine. For practical rea-
sons, it was not possible to monitor the exercise sessions of each
individual, and we had to rely on their cooperation in this regard.
During a two-week washout period prior to the study, our sub-
jects were instructed to consume their habitual diet with no alco-
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holic beverages and to take no medications that may influence the
platelet aggregation and lipoprotein profile. After the subjects had
fasted overnight, plasma lipid concentrations, platelet aggregation,
fasting glucose and insulin levels, uric acid and vascular inflam-
matory marker concentrations were measured at baseline, after four
weeks of diet and after four weeks of diet plus wine, as well as
body weight, abdominal circumference and blood pressure. 
To determine the atherogenic lipoprotein profile associated with
the metabolic syndrome, various biochemical and inflammatory
parameters were determined in all 12 subjects. Fasting blood sam-
ples were analysed for TC, TG, HDLC, LDLC, TC/HDL ratio and
uric acid. Insulin resistance was measured by determining fasting
blood glucose and insulin concentrations, and determining the glu-
cose/insulin ratio. Hypersensitive C-reactive protein (hs-CRP),
FVIII, fibrinogen and vWF were measured to determine vascular
inflammation as a marker of atherogenesis. The changes in the pro-
coagulants and anticoagulants in our participants during the exper-
imental period were measured by determining the platelet count,
platelet coagulation, platelet membrane fluidity, plasma TxB2, tPA,
PAI-1 (fibrinolytic markers), and FVII (affected by dietary triglyc-
erides). The samples were analysed by PathCare Laboratories,
Cape Town, with a Beckman Coulter LX 20 analyser.
To measure the antioxidant effect of the diet and wine inter-
ventions respectively, the oxygen radical absorbance capacity
(ORAC) (Ou et al., 2001) was determined on the plasma of all the
subjects at baseline, after the four-week period on the diet with-
out wine, and after the four-week period on the diet with red
wine. 
A genetic screen for genetic markers that can be triggered by
lifestyle risk factors such as smoking, physical inactivity or
unhealthy food choices that manifest as CVD was carried out on
all the participants to support the clinical diagnosis (Kotze and
Badenhorst, 2005). The genetic profile was also built to deter-
mine the polymorphisms of genes involved in lipoprotein metab-
olism or atherosclerosis and to search for interactions between
gene polymorphisms and response to diet and alcohol. A risk
assessment, linked to nutrition and lifestyle, which targeted the
interaction between genes and the environment was done for each
participant. By combining genetic testing for both monogenic and
multi-factorial conditions, it is possible to distinguish between
patients with familial hypercholesterolemia (FH), which requires
lifelong drug treatment, and those at increased CVD risk as a con-
sequence of other risk factors that can be managed effectively by
dietary and other lifestyle modifications. (Kotze and Badenhorst,
2005). Genetic testing was performed as previously described,
using a reverse-hybridisation strip-assay technique (Kotze et al.,
2003). This technique involves (1) DNA isolation from anticoag-
ulated blood, (2) amplification of relevant gene sequences and
terminal labelling with a reporter molecule, and (3) selective
hybridisation of the amplification products to allele-specific
(wild-type or mutant) oligonucleotide probes in separate cavities
of a micro-well plate and detection by immunoreaction. The FH
strip-assay (Kotze et al., 2003) was used in combination with a
multi-gene CVD assay (Kotze et al., 2003), which includes 
12 functional genetic changes in 10 different genes. These
include mutation 10708G→A in the apolipoprotein B (ApoB)
gene, mutations 4075C→T (E2 allele) and 3937T→C (E4 allele)
in the apolipoprotein E (Apo E) gene, 677C→T and 1298A→C
in the methylenetetrahydrofolate reductase (MTHFR) gene,
20210G→A in the factor II (prothrombin) gene, 1691G→A in the
factor V gene, 103G→T in the factor XIII gene, 455G→A in the
β-fibrinogen gene, 1565T→C in the glycoprotein IIb/IIIa
(GPIIIa) gene, the 4G/5G polymorphism in the plasminogen acti-
vator inhibitor-1 (PAI-1) gene, and mutation 845G→A in the
HFE gene involved in iron overload. The 4G/5G polymorphism
in the plasminogen activator inhibitor (PAI-1) gene is also asso-
ciated with metabolic syndrome, insulin resistance and type II
diabetes, and protein levels are increased by emotional or psy-
chosocial stress and inflammation.
For statistical analysis of the data, repeated measures of analy-
sis of variance were used. In all cases, normal probability plots of
the residuals were inspected for possible outliers. A 5% signifi-
cance level was used as guideline for determining significant dif-
ferences.
RESULTS
In this study, statistically significant changes were found in the
anthropometric parameters relating to the measurement of body
weight (Figure 2) and systolic blood pressure. Body weight
decreased significantly (p = 0.04), and systolic blood pressure
(Figure 3) decreased (p = 0.045) during the experimental period.
A trend for the abdominal circumference to decrease (p = 0.059)
was observed. 
FIGURE 1
After a two-week washout period, three women and nine men consumed a
Mediterranean-type diet without and with red wine respectively for four weeks.
Blood samples were taken at baseline, after four weeks of diet without wine, and
after four weeks of diet plus wine.
FIGURE 2
Participants demonstrated a statistically significant weight loss over the two-
month intervention period. The error bars on the graph indicate 95% confidence 
intervals for the estimated means.
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There was a statistically significant increase in the ORAC
(Figure 4) after the four-week diet intervention period, from 7.5
± 1.4 mmol/L trolox equivalents (TE) to 9.3 ± 2.5 mmol/L TE,
p = 0.035. The ORAC decreased when wine was added to the diet
(to 8.5 ± 1.1 mmol/L TE, but this was not statistically significant
(p = 0.342), and the increase in the ORAC was still significantly
different from baseline levels (p = 0.04) (Table 1). 
The atherogenic and prothrombotic serum lipoprotein profiles,
uric acid, insulin and fasting glucose did not change significantly
during the study period, nor did the inflammatory markers com-
pared to baseline values. The addition of red wine to the
Mediterranean-type diet did not add any beneficial or detrimental
changes to the measured biochemical markers of the metabolic
syndrome.
The genetic assessment demonstrated different combinations of
genetic risk factors that may interact with diet and lifestyle fac-
tors, unique to each individual tested. All 12 study participants
had one or more genetic risk factors involved in lipid metabolism,
folate metabolism (high homocysteine levels), haemostasis or
insulin resistance. Notably, two subjects included in the study
have FH and four tested positive for the E4 allele of the
apolipoprotein E (Apo E) polymorphism that interacts with
smoking, alcohol and dietary factors to increase the risk of CVD.
Detection of both the factor V Leiden (1691G→A) and pro-
thrombin mutations (20210G→A) in one individual was of spe-
cial concern, as the combined effect of these two mutations is
associated with a 40-fold increased risk of venous thrombosis.
The risk is further increased in the presence of obesity, which was
noted in the subject, and the low physical activity reported.
DISCUSSION
The Mediterranean-type diet had a protective effect against the
metabolic syndrome, by significantly lowering the body weight
and systolic blood pressure after the diet and the diet with wine
period. The Mediterranean diet influenced the antioxidant poten-
tial of the serum, whereas red wine had no significant additional
in vivo antioxidant effects.
In a pilot study on healthy subjects, we found that an interven-
tion with the Mediterranean-type diet and red wine could influ-
ence the impaired response to the physiological effects of insulin,
FIGURE 3
A statistically significant drop in the systolic blood pressure was observed after the
diet intervention, which remained significant even after the addition of red wine.
The error bars on the graph indicate 95% confidence intervals for the estimated 
means.
FIGURE 4
The statistically significant increase in the plasma oxygen radical absorbent
capacity indicated that the subjects made significant changes to their diet during
the experimental period. The error bars on the graph indicate 95% confidence 
intervals for the estimated means.
TABLE 1
Chemical and biochemical characteristics of the participants after
diet and diet plus wine interventions.
Test Baseline Diet Wine + Diet p-value
Abd circum 113.63±2.75 111.38±3.22 110.25±2.42 0.058
Weight 102.75±3.99 101.75±3.88 101.46±3.89 0.04
Systolic BP 138.33±5.12 126.67±2.56 133.75±3.65 0.044
Diastolic BP 90±2.3 87.91±2.52 86.67±2.16 0.23
Fasting glucose 5.53±0.25 5.49±0.32 5.54±0.31 0.915
Insulin 12.41±1.38 13.07±1.93 12.75±2.22 0.872
Gluc/Ins 0.5±0.06 0.52±0.07 0.55±0.08 0.63
Tot Chol 6.35±0.58 6.33±0.6 6.68±0.72 0.194
HDL 0.98±0.06 0.93±0.06 0.98±0.06 0.14
TC/HDL 6.56±0.56 6.93±0.68 6.82±0.76 0.223
LDL 4.51±0.51 4.8±0.54 4.75±0.62 0.296
TG 1.97±0.27 1.84±0.25 2.07±0.29 0.276
Urate 0.37±0.02 0.37±0.02 0.37±0.02 0.562
ORAC 7.45±0.40 9.31±0.71 8.52±0.32 0.043
CRP 6.29±1.97 6.91±2.73 6.64±2.43 0.733
including those on glucose and lipid metabolism. In these sub-
jects there was a statistically significant weight loss, an increase
in HDL-C and a reduction in blood glucose levels during the diet
and wine intervention period.
In contrast to these findings, we found no significant statistical
differences in any of the biochemical parameters that were mea-
sured in our subjects during the short intervention study period. Our
subjects with the features of the metabolic syndrome, who were at
high global risk for CVD (hypertension, hyperglycaemia, athero-
genic dyslipidemia, abdominal obesity and physical inactivity),
were remarkably resistant to changes in the biochemical parameters. 
We can speculate that the biochemical abnormalities of patients
with the metabolic syndrome may need a longer intervention
period to change (Esposito et al., 2004) All the participants in this
study demonstrated features of insulin resistance, which could
also contribute to the resistance to improvement in the biochemi-
cal parameters of the metabolic syndrome. The metabolic abnor-
malities associated with the metabolic syndrome may induce
upregulation of the vascular inflammatory-thrombogenic state,
S. Afr. J. Enol. Vitic., Vol. 28, No. 1, 2007
48 Wine, Diet and the Metabolic Syndrome
and this may be responsible for the inefficiency of the anti-throm-
botic and anti-atherogenic effects of the Mediterranean-type diet
and red wine intervention.
Genetic testing of our subjects demonstrated three different
genotypes that may respond differently to diet and alcohol inter-
ventions. The two subjects with FH require lifelong drug therapy.
The four ApoE4 allele carriers did not experience an increase in
HDL-C associated with alcohol intake, and were more responsive
to diet and less responsive to statin therapy than ApoE2 allele car-
riers (Djousse, 2004).
By combining genetic testing for both monogenic and multi-
factorial conditions, it was possible to distinguish between
patients with FH requiring lifelong drug treatment and those at
increased CVD risk as a consequence of other risk factors that
can be managed effectively by dietary and other lifestyle modifi-
cations. Failure to demonstrate similar effects following dietary
intervention in healthy individuals compared with the current
study group of patients with the metabolic syndrome highlights
the importance of genetic assessments as part of intervention pro-
grammes. Treatment requirements or therapeutic responses may
differ due to the genetic background of the individual. Our find-
ings may be explained partly by the diverse genetic profile iden-
tified among the study participants, as 50% of our cases had
mutations involved in lipid metabolism that may influence the
response to dietary intervention and alcohol consumption.
The limitation of this study is that we had only a small cohort of
subjects, and we monitored them over only an eight-week inter-
vention period. Because wine was not given randomly in the first
or second period, it could be that the compliance in the second peri-
od was reduced in comparison to the first, which could obscure the
effects of wine. Our subjects also demonstrated three different
genotypes that respond differently to diet and alcohol interventions.
Subjects with FH require lifelong drug therapy. ApoE4 allele carri-
ers do not experience an increase in HDL associated with alcohol
intake, are more responsive to diet and are less responsive to statin
therapy than ApoE2 allele carriers (Mukamal et al., 2004).
People demonstrating the features of the metabolic syndrome
are habitually physically inactive, and it is known that the clus-
tering atherogenic and diabetogenic abnormalities of the meta-
bolic syndrome are highly prevalent in sedentary populations. An
increase in physical activity in these patients is probably the most
difficult factor to deal with on the epidemiological scale. We did
not accurately control the amount and intensity of the exercise
prescription, and all participants probably did not adhere to our
recommendations to include 20 to 30 min of moderate-intensity
exercise in their daily routine. 
The significant weight loss, slight decrease in abdominal cir-
cumference, and significant reduction in systolic BP are encour-
aging signs and support the view that the abnormal clinical fea-
tures of the metabolic syndrome do respond rapidly to lifestyle
interventions such as dietary modifications and mild exercise. 
There was a statistically significant increase in the ORAC after
the four-week diet intervention period. This may be attributed to
the olive oil-based, alpha-linolenic acid-rich, Mediterranean-type
diet. The ORAC decreased slightly when wine was added to the
diet, but this was not statistically significant and the increase in
the ORAC was still significantly different from baseline levels. 
The latter finding was unexpected, because the red wines used
in this project had a very high concentration of polyphenols (2.6
g gallic acid/L) on average. Wine polyphenols have proven in
vitro antioxidant properties. The total antioxidant capacity of the
12 red wines used in this project was 19.02 mM TE. The high
alcohol content (12 to 15%) could negate the antioxidant effects
of the polyphenols, because ethanol on its own demonstrates
oxidative properties, and we had a 33% Apo E4 polymorphism
among our test subjects, which correlates well with the finding of
Kotze et al. (2003).
A more feasible explanation of this phenomenon could be that,
despite their potent in vitro actions as antioxidants, anti-inflamma-
tory and anti-cancer agents, the effective concentrations of wine
polyphenols are relatively unattainable by virtue of their poor
bioavailability and/or their conjugation prior to absorption
(Hollman et al., 1997). The increase in the antioxidant potential in
the serum could mostly be ascribed to the high intake of fruits,
grains, vegetables and extra virgin olive oil, and the decrease in red
meat consumption in the Mediterranean-type diet during the inter-
vention period, and is unrelated to the red wine intake in our study.
This research suggests that the addition of red wine to the
Mediterranean-type diet does not demonstrate any additional bene-
ficial or detrimental effects apart from the diet on its own on any of
the biochemical parameters that we measured during this short
intervention period. Although the antioxidant potential of the serum
did increase significantly during the diet intervention, this had no
sufficient influence on the inflammatory markers, insulin sensitivity
or lipid profile during this short intervention period. In order to
demonstrate sustainable benefits, we will have to follow the subjects
over a longer period of time to observe the beneficial effects of these
lifestyle interventions on the features of the metabolic syndrome.
Furthermore, because wine is arguably the healthiest form of
alcoholic beverage, its moderate consumption should be considered
an important component of a healthy diet and lifestyle. Moderate
alcohol consumption may be a marker of a healthy lifestyle, and
should therefore not be considered in isolation from other aspects of
lifestyle, such as cigarette smoking, inactivity and diet. The limited
epidemiological data linking wine consumption to superior health
outcomes compared with drinkers of other alcoholic beverages war-
rants further research to identify a plausible mechanism.
CONCLUSIONS
This study indicates that the Mediterranean diet can beneficially
influence the early clinical diagnostic criteria relating to the meta-
bolic syndrome during a short-term intervention period. The addi-
tion of red wine to the diet demonstrated no additional health ben-
efits or detrimental effects.
It must be acknowledged that the aetiology of coronary heart dis-
ease is multi-factorial, that risk factors have a multiplicative effect,
and that physicians have to deal holistically with patients, and not
with isolated risk factors. At the same time, the prevention of coro-
nary heart disease is multifaceted, and wine cannot be seen in iso-
lation from other preventative strategies such as exercise, healthy
diet and weight loss. The influence of wine on health should there-
fore not be seen in isolation, but as part of a healthy lifestyle.
The molecular mechanisms through which the additional bene-
fits of the polyphenols and other substances in wine are realised,
as well as the tendency of wine to be consumed regularly, with
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meals and in moderation, need to be explained by continued and
focused scientific research. More investigations are needed on the
bioavailability of the polyphenols in wine before any health claims
relating to the non-alcoholic components of wine can be made. 
A genetic screen should be done on patients with dyslipidaemia
to clarify the interplay between genotype and environment in defin-
ing susceptibility to illness and determining the appropriate thera-
py. It will also demonstrate how the genotype varies amongst
cohorts of patients, and especially the role of such variation in the
causation of important illnesses and in responses to pharmaceuti-
cals and dietary interventions. Physicians should incorporate genet-
ic testing as an integral part of clinical and laboratory assessments
to identify patients with very early evidence of reversible disease,
as manifested by endothelial dysfunction, early markers of chronic
inflammation, or symptoms and signs of the metabolic syndrome. 
Additional investigation is needed to determine the influence of
wine and alcohol on improving endothelial dysfunction, combat-
ing the damaging effects of low-grade chronic inflammation of
the endothelium, and preventing the premature onset of the meta-
bolic syndrome. The challenge will be to identify symptom-free,
high-risk individuals and act to reduce their risk factor levels
through lifestyle, environmental, social and economic interven-
tions. Wine, as part of a healthy, Mediterranean-type diet and
lifestyle, could play a role in this regard, but may not be benefi-
cial for individuals with certain genetic predispositions.
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